Skip to main content
Premium Trial:

Request an Annual Quote

Sirna Therapeutics and Invitrogen and DNA Research Innovations

Premium

Sirna Reports 70-percent drop in Q3 Revenues

Sirna Therapeutics reported last week its financial results for the third quarter 2004, posting a sharp drop off in revenues amid a decline in expenses.

Sirna’s revenues for the third quarter were $84,000, compared with $283,000 in the year-ago period. The company attributed the 70 percent decline to the completion of ribozyme-related manufacturing programs as its new aptamer manufacturing arrangement with Archemix gets underway.

Sirna’s third-quarter expenses were $7.9 million, down from $11.2 million in the same period a year earlier. The company’s expenses in the third quarter of 2003 included a $6 million expense related to the acquisition of a license to RNAi-related intellectual property from the University of Massachusetts, Sirna noted.

Adjusting for the one-time licensing expense, Sirna’s net loss for the third quarter 2004 rose 57 percent over the year-ago quarter to $7.8 million. The company attributed the increase to its earlier-than-expected filing of an investigational new drug application for its age-related macular degeneration drug Sirna-027, as well as the costs associated with its ongoing hepatitis C program.

As of Sept. 30, Sirna had cash, cash equivalents, and securities available for sale totaling $35.1 million.


Invitrogen Acquires DNA Research Innovations, Posts Higher Q3 Profit

Invitrogen said last week that it has acquired nucleic acid-purification company DNA Research Innovations for up to $65 million.

Under the terms of the deal, Invitrogen paid DNA Research Innovations $35 million in cash upfront, and has agreed to pay up to $30 million more based on the achievement of undisclosed research and development milestones.

The deal gives Invitrogen control of the company’s ChargeSwitch nucleic acid-purification technology, which can be used with either DNA or RNA in a range of formats, and includes manual purification of a few samples for high throughput automated applications, the companies said. The platform can be used in bacteria, tissues, blood, forensic samples, and buccal cells.

Invitrogen also posted last week third-quarter revenues of $256.3 million, up from $197 million in the year-ago period, as the company benefited from strong sales in its BioDiscovery and BioProduction businesses.

Research and development spending also increased in the third quarter, to $19.2 million from $15.4 million year over year, while Invitrogen’s net income climbed to $28.7 million from $13.7 million.

As of Sept. 30, Invitrogen had cash and investments totaling $939.8 million.

 

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.